Citius Pharmaceuticals Inc. Common
$0.56
-$0.00 (-0.02%)
$0.56Day Range$0.57
Key Statistics
Market Cap
$15.38M
Shares Outstanding
27.5M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Oct 18, 2011
Round Lot
100
Locale
US
Trading Data
Day Open
$0.56
Day High
$0.57
Day Low
$0.56
Volume
139.3K
VWAP
$0.56
Prev Close
$0.56
Transactions
--
Acc. Volume
--
About Citius Pharmaceuticals Inc. Common
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.
PHARMACEUTICAL PREPARATIONSSIC 283423 employees11 COMMERCE DRIVE, CRANFORD, NJ, 07016(908) 967-6676IPO Oct 18, 2011US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001506251
- Composite FIGI
- BBG001QQH2N3
- Share Class FIGI
- BBG001V1J7S4
- Ticker Root
- CTXR
- SIC Code
- 2834
About Citius Pharmaceuticals Inc. Common (CTXR) Stock
Citius Pharmaceuticals Inc. Common (CTXR) closed the 2026-09-16 session at $0.56, down 0.02% versus the previous close (-0.00). The stock opened at $0.56 and traded between $0.56 and $0.57 during that session. Session trading volume was 139K shares. The volume-weighted average price (VWAP) is $0.56.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.
Citius Pharmaceuticals Inc. Common has a market capitalization of $15.4 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. CTXR is listed on the XNAS exchange. The company employs approximately 23 people. Citius Pharmaceuticals Inc. Common is headquartered in CRANFORD, NJ. The recorded listing date is 2011-10-18.
On this page you can find market CTXR stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.